A retrospective analysis of the safety and activity of Lutetium-177-PSMA radionuclide treatment in older patients with metastatic castration-resistant prostate cancer.

CONCLUSION: Our results indicate that Lu-PSMA is safe and active in elderly patients with mCRPC.
IMPLICATION FOR PRACTICE: Lutetium-177-PSMA (Lu-PSMA), a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA), enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer (mCRPC). The recently published single-arm phase II trial with LU-PSMA, describing its safety and activity, did not include patients over 75. We retrospectively analyzed Lu-PSMA activity in patients over 75 and found that treatment was tolerable and similarly active in this age group, with no new emerging safety signals. Albeit our small cohort size, our analysis suggests that Lu-PSMA can serve as an advanced palliative treatment line in mCRPC in elderly patients.
PMID: 32430954 [PubMed - as supplied by publisher]

Source: The Oncologist - May 18, 2020 Category: Cancer & Oncology Authors: Leibowitz R, Davidson T, Gadot M, Aharon M, Malki A, Levartovsky M, Oedegaard C, Saad A, Sandler I, Ben-Haim S, Domachevsky L, Berger R Tags: Oncologist Source Type: research